**Leonid A. Opryatin1, Tatiana E. Borovik1, 2, Elena A. Roslavtseva1, Nikolay N. Murashkin1, 2, 3**

1 National Medical Research Center of Children’s Health, Moscow, Russian Federation

2 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation

3 Central State Medical Academy, Moscow, Russian Federation

**Celiac Disease Prevalence Among Children with Dermatologic Pathology: Cross-Sectional Study with Clinical Case Series**

**Corresponding author:**

*Opryatin Leonid A.*, doctor in department of dermatology with laser surgery group in the Center for Pediatric dermatology, bench scientist in the laboratory of skin pathology in children of the Department of scientific research in pediatrics of National Medical Research Center of Children’s Health

**Address:** 119296, Moscow, Lomonosovsky Ave., 2, b. 1, **phone:** +7 (495) 967-14-20, **e-mail:** opryatin.l@gmail.com

**Article received:** Jul 12, 2021, **accepted for publication:** Oct 22, 2021

***Background.*** *Celiac disease (gluten enteropathy) is relatively rare disease. However, such patients have higher risk of skin pathology than general the population, and their therapy efficacy is limited by the use of gluten-free diet. Therefore, screening of dermatologic patients on celiac disease may be relevant.* ***Objective****. Our aim was to study the prevalence of celiac disease among children with skin pathology.* ***Methods.*** *The study included children hospitalized in dermatology department. Screening for celiac disease included detection in blood serum of antibodies (IgA, IgG, IgM) to tissue transglutaminase via rapid tests. In case of positive result of rapid test, we have repeated the estimation of antibodies (IgA, IgG) to tissue transglutaminase via immunochemiluminescent method with ImmunoCAP technology or via enzyme immunoassay. In case of positive serological test, we have performed HLA typing to determine haplotypes of DQ2 and DQ8, as well as esophagogastroduodenojejunoscopy (EGDJS) with biopsy of the duodenal and jejunal mucosa for further histological verification of the diagnosis.* ***Results.*** *We examined 1,000 children with various dermatologic pathologies. Rapid tests showed positive result in 21 patients (2.1%; 95% CI 1.3–3.2%). The presence of antibodies to tissue transglutaminase was confirmed via additional serological examination in all cases. HLA-haplotypes DQ2/8 were revealed in all patients with positive rapid test results. Typical form of gluten enteropathy was confirmed in 18/21 patients (86%) according to a histological study, thus, estimated prevalence of celiac disease is 1.8% (95% CI 1.1–2.8%).* ***Conclusion.*** *The prevalence of celiac disease remains underestimated among children with skin diseases. More studies are needed on the diagnostic features of rapid tests on tissue transglutaminase, as well as the benefits of screening for celiac disease to achieve patient-relevant clinical outcomes of skin pathology with wider gluten-free diet.*

***Keywords:*** *children, skin diseases, celiac disease, rapid tests, tissue transglutaminase, antibodies*

***For citation***: Opryatin Leonid A., Borovik Tatiana E., Roslavtseva Elena A., Murashkin Nikolay N. Celiac Disease Prevalence Among Children with Dermatologic Pathology: Cross-Sectional Study with Clinical Case Series. *Voprosy sovremennoi pediatrii — Current Pediatrics*. 2021;20(5): 402–406. (In Russ.) <https://doi.org/10.15690/vsp.v20i5.2313>

**STUDY LIMITATIONS**

The sample size is limited by the number of rapid tests available in the study. The larger sample could identify other rarer dermatoses associated with celiac disease, as several previous studies have shown. It was impossible to estimate the prevalence of celiac disease separately in each skin pathology considering this pathology rarity. Thus, the obtained result on celiac disease prevalence applies only to the population of patients with dermatological pathology. Moreover, the sample in this study contained only hospitalised patients who differ from the general population of patients with dermatological diseases. This fact may affect the celiac disease prevalence estimations presented above.

The diagnostic sensitivity of the rapid test for antibodies to tissue transglutaminase is, on average, relatively high (85.7%) according to the manufacturer's instruction. However, it cannot be excluded that rapid tests could miss about 30% of celiac disease cases in our sample as the lower threshold of 95% CI for this diagnostic parameter is 69.7%. Thus, it is possible that actual celiac disease prevalence among patients with skin diseases can be significantly higher.

**FINANCING SOURCE**

The purchase of rapid tests for research was funded by National Medical Research Center of Children’s Health.

**DISCLOSURE OF INTEREST**

**Nikolay N. Murashkin** — receiving research grants from pharmaceutical companies Janssen, Eli Lilly, Novartis, AbbVie, Pfizer, Amryt Pharma plc. Scientific consultant of Galderma, Pierre Fabre, Bayer, LEO Pharma, Pfizer, AbbVie, Zeldis Pharm.

The other contributors confirmed the absence of a reportable conflict of interests.